Xcout Intel
Flex Pharma competitors & alternatives
The 12 closest competitors and alternatives to Flex Pharma among pharmaceuticals companies — ranked by similarity to what Flex Pharma actually does, not by market-cap band.
Subscribe to see Flex Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Flex Pharma
Flex Pharma is a specialty pharmaceutical company that develops advanced drug delivery formulations to enhance the bioavailability, tolerability, and dosing flexibility of complex or poorly soluble drugs. The company utilizes its proprietary ElectroNanoSpray (ENS) technology platform to assist pharmaceutical innovators in optimizing drug performance for clinical trials and patient care.
Flex Pharma at a glance
Flex Pharma is a pharmaceuticals company headquartered in United States. Xcout tracks 5 named people at Flex Pharma, including Christian F. Wertz (President).
Flex Pharma leadership
- Christian F. WertzPresident
- Jennifer PilateVice President, Regulatory
- Sue SchillingVice President, Quality
- Huijing FuSr Director, Pharm Tech & Engineering
- Joe McTarsneySr Director, Pharmaceutical Sciences
Top 12 Flex Pharma competitors
Ranked by semantic similarity — how close each company is to Flex Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
MedPharm is a privately held pharmaceutical development company with its global headquarters in Guildford, United Kingdom, partnering with clients worldwide to design topical, transdermal, and complex drug products.
Similar pharmaceuticals company
Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.
Pharmaceuticals & Biotechnology
INTREPID Robotics, Inc. provides an AI-driven drug formulation platform designed to accelerate therapeutic development for pharmaceutical and biotechnology companies. The company combines artificial intelligence, automation, and formulation expertise to convert candidate molecules into optimized, manufacturable drug formulations.
Biotechnology & Pharmaceuticals
Denovo Sciences Inc. is an AI-driven drug discovery company developing proprietary technologies and automated systems for early-stage small-molecule discovery and single-cell analysis. The company has collaborated with international partners to address unmet medical needs.
Similar pharmaceuticals company
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.
Similar pharmaceuticals company
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Similar pharmaceuticals company
Mindset Pharma Inc. is a drug discovery and development company based in Toronto, Canada, focused on creating optimized, patentable next-generation psychedelic medicines.
Biotechnology
Fulgent Pharma LLC is a clinical-stage pharmaceutical company that develops innovative cancer therapeutics using a patented nanoencapsulation technology. The company focuses on improving existing chemotherapy drugs and creating new drug candidates to treat various cancers while reducing toxicity and enhancing drug delivery and safety.
Health Care
Disruptive Pharma develops and commercializes Formulite, a proprietary platform technology designed to enhance the solubility, oral bioavailability, and overall properties of pharmaceutical compounds. The company provides drug development solutions that enable optimized pill sizes and eco-friendly manufacturing for pharmaceutical partners.
Biotech
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Biotechnology
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Biotech
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Flex Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Flex Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →